Peter Schmid, MD, PhD

Videos

Addition of Pembrolizumab to Neoadjuvant Chemotherapy Plus Adjuvant Pembrolizumab Improved EFS Among Patients with Early-Stage Triple-Negative Breast Cancer

12/08/2023

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.

Peter Schmid, MD, PhD, presents...

12/08/2023

Oncology

Videos

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer

09/15/2024

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...

Peter Schmid, MD, PhD, discusses...

09/15/2024

Oncology